Yahoo! Finance Search - Finance Home - Yahoo! - Help

Friday, September 30 2016 7:14pm ET - U.S. Markets Closed.
Industry Center - Biotechnology
Industry Center > Biotechnology > News
More On This Industry
· Summary
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Biotechnology News
Latest News
Friday, Sep 30, 2016
·IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Seres Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Business Wire - 10 minutes ago
·SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Seres Therapeutics, Inc. (MCRB) & Lead Plaintiff Deadline: November 28, 2016
PR Newswire - 1 hour, 4 minutes ago
·Gilead Sciences: Are Hepatitis C Sales Improving?
at - 1 hour, 8 minutes ago
·What Do Analysts Say about Regeneron’s Upside Potential?
- 1 hour, 8 minutes ago
·Emergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDC
GlobeNewswire - 1 hour, 45 minutes ago
·SEC Issues Charges Over Biotech Insider Activity
- 2 hours, 3 minutes ago
·Emergent BioSolutions Awarded BARDA Contract for Advanced Development and Delivery of NuThrax, a Next Generation Anthrax Vaccine, Valued at Up to $1.6 Billion
GlobeNewswire - 2 hours, 9 minutes ago
·Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Mirataz to FDA and Launches KindredBio Equine Website
PR Newswire - 2 hours, 13 minutes ago
·Call buyers looking for more in Exelixis
optionMONSTER - 2 hours, 28 minutes ago
·Enanta Pharmaceuticals Announces AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Business Wire - Fri 8:08 am ET
·AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
PR Newswire - Fri 8:00 am ET
·Health Canada Approves First Teligent Topical Product
PR Newswire - Fri 8:00 am ET
·Regeneron's Eylea combination therapy fails mid-stage study
Reuters - Fri 7:43 am ET
Thomson Reuters ONE - Fri 7:16 am ET
·Biotech Stock Mailbag: Dynavax, Puma, Ariad
at - Fri 7:00 am ET
·Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration
PR Newswire - Fri 7:00 am ET
·BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule
PR Newswire - Fri 7:00 am ET
·Struggling ImmunoGen to cut 65 jobs in cost-saving measure
at - Fri 6:40 am ET
·OncoSec to Host Fourth Quarter and Fiscal Year End Financial Results Conference Call on October 13, 2016
PR Newswire - Fri 6:01 am ET
·Sinovac Schedules 2016 Annual Meeting of Shareholders
PR Newswire - Fri 6:00 am ET
More Latest News...

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Biotechnology Headlines
More Finance RSS Feeds

Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2016, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?